Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Y-90 resin microspheres with camrelizumab and/or apatinib or Y-90 alone versus cTACE for unresectable or non-ablatable non-metastatic hepatocellular carcinoma
CTR20252438Phase 2Active
- Sponsor
- Sirtex
- Start
- Aug 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
A Phase 2 trial of yttrium-90 resin microspheres, camrelizumab, Rivoceranib in hepatocellular carcinoma (HCC), sponsored by Sirtex. Started Aug 2025; status: active.
02
Drugs
yttrium-90 resin microspherescamrelizumabRivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20252438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252438.